<DOC>
	<DOC>NCT01214616</DOC>
	<brief_summary>- To identify the Maximum Tolerated Dose (MTD) of afatinib in combination with vinorelbine i.v. by assessment of Dose Limiting Toxicities (DLT); - To assess safety and anti-tumour efficacy and determine pharmacokinetic characteristics of afatinib and vinorelbine i.v.</brief_summary>
	<brief_title>BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Inclusion criteria: Histologically confirmed diagnosis of malignancy that is advanced and for which standard therapies do not exist or are no longer effective. Life expectancy at least 12 weeks Eastern Cooperative Oncology Group Performance Status 0 or 1 Adequate hepatic, renal, haematologic and other organ function Written informed consent Exclusion criteria: Chemotherapy, immunotherapy, surgery and radiotherapy within the past 4 weeks Prior treatment with afatinib and or vinorelbine Clinically significant active infectious disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>